ARID1A Is a Prognostic Biomarker and Associated with Immune Infiltrates in Hepatocellular Carcinoma.

Authors:
Feng Y; Tang X; Li C; Su Y; Wang X and 4 more

Journal:
Can J Gastroenterol Hepatol

Publication Year: 2022

DOI:
10.1155/2022/3163955

PMCID:
PMC8752298

PMID:
35028302

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Can J Gastroenterol Hepatol

Abbreviation: Can J Gastroenterol Hepatol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Hepatitis C Attributable Healthcare Costs and Mortality among Immigrants: A Population-Based Matche…
Erman A; Sahakyan Y; Everett K and 6 more (2024) - Transparency Score: 3/6
Prevalence of Esophageal Eosinophilia, Eosinophilic Esophagitis, and Lymphocytic Gastritis in Child…
Alaifan MA; Khayat A; Bokhary RY and 4 more (2024) - Transparency Score: 2/6
Construction and Analysis of Hepatocellular Carcinoma Prognostic Model Based on Random Forest.
Wang Y; Ma L; Xue P and 6 more (2023) - Transparency Score: 3/6
Diabetes and Metabolic Disorders: Their Impact on Cardiovascular Events in Liver Transplant Patient…
Di Cola S; Cusi G; Lapenna L and 6 more (2023) - Transparency Score: 2/6
Disparate Intent-to-Treat Outcomes for Pediatric Liver Transplantation Based on Indication.
Lang A; Goff C; Montgomery A and 4 more (2023) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of Interest The authors declare that there are no conflicts of interest."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025